Abstract PO-055: Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer
Susan Tsai(The Ohio State University Wexner Medical Center), Jen Jen Yeh(University of North Carolina at Chapel Hill), Mandana Kamgar(Medical College of Wisconsin), Jason D. Merker(Dana-Farber Brigham Cancer Center), Naim U. Rashid(Dana-Farber Cancer Institute), Erkut Borazanci(HonorHealth), Douglas B. Evans(The University of Texas MD Anderson Cancer Center), Margaret L. Gulley(University of North Carolina at Chapel Hill), Bryan Hunt(Medical College of Wisconsin), Phillip Chisholm(Medical College of Wisconsin), Abdul H. Khan(Aligarh Muslim University), Tamara Giorgadze(Medical College of Wisconsin), William A. Hall(Medical College of Wisconsin)
Cited by 3
Related Papers
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
|Journal of Clinical Oncology|2018|925
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
|Clinical Cancer Research|2017|635